Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$1.14 -0.9%	$1.25	$0.87 ▼ $2.55	$21.69M	0.43	222,455 shs	167,180 shs
LGVN Longeveron	$1.46 -0.7%	$1.33	$1.14 ▼ $4.88	$21.94M	0.21	735,977 shs	104,892 shs
SLGL Sol-Gel Technologies	$8.18 +1.9%	$7.47	$3.34 ▼ $16.50	$22.34M	1.09	33,158 shs	6,653 shs
TCRT Alaunos Therapeutics	$3.25 -3.8%	$3.58	$1.31 ▼ $6.20	$5.54M	-0.79	142,434 shs	41,316 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	-0.87%	-2.56%	-7.32%	+1.79%	+1.79%
LGVN Longeveron	-0.68%	-2.67%	+13.18%	0.00%	-58.52%
SLGL Sol-Gel Technologies	+2.89%	+12.68%	+13.15%	+48.64%	-5.24%
TCRT Alaunos Therapeutics	-3.85%	-35.13%	+1.56%	+31.05%	-47.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	2.7849 of 5 stars	3.5	3.0	2.7	1.7	0.6
LGVN Longeveron	3.4728 of 5 stars	3.6	4.0	2.7	1.7	1.3
SLGL Sol-Gel Technologies	3.185 of 5 stars	3.5	5.0	2.2	1.7	0.6
TCRT Alaunos Therapeutics	0.5957 of 5 stars	0.0	2.0	4.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	645.61% Upside
LGVN Longeveron	3.25	Buy	$8.67	493.61% Upside
SLGL Sol-Gel Technologies	3.00	Buy	$40.00	389.30% Upside
TCRT Alaunos Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRT, SLGL, LGVN, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
LGVN Longeveron	$2.23M	9.80	N/A	N/A	$1.47 per share	0.99
SLGL Sol-Gel Technologies	$11.54M	1.98	N/A	N/A	$10.36 per share	0.79
TCRT Alaunos Therapeutics	$10K	533.00	N/A	N/A	$1.29 per share	2.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.76	N/A	N/A	N/A	N/A	-106.70%	-82.18%	8/20/2025 (Estimated)
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-760.72%	-85.07%	-70.74%	8/13/2025 (Estimated)
SLGL Sol-Gel Technologies	-$10.58M	-$4.70	N/A	N/A	N/A	-107.78%	-43.98%	-35.28%	8/15/2025 (Estimated)
TCRT Alaunos Therapeutics	-$4.68M	-$2.54	N/A	∞	N/A	N/A	-169.34%	-124.28%	8/13/2025 (Estimated)

Latest TCRT, SLGL, LGVN, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	N/A	N/A	N/A	$0.41 million	N/A
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/15/2025	Q1 2025	TCRT Alaunos Therapeutics	-$4.50	-$0.67	+$3.83	-$0.67	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	5.33	5.33
LGVN Longeveron	N/A	5.61	5.61
SLGL Sol-Gel Technologies	N/A	5.12	5.12
TCRT Alaunos Therapeutics	N/A	1.00	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
LGVN Longeveron	10.01%
SLGL Sol-Gel Technologies	26.18%
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
LGVN Longeveron	11.20%
SLGL Sol-Gel Technologies	66.51%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
LGVN Longeveron	20	14.93 million	13.26 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable
TCRT Alaunos Therapeutics	40	1.64 million	1.38 million	No Data

TCRT, SLGL, LGVN, and CMMB Headlines

Recent News About These Companies

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

May 14, 2025 | globenewswire.com

Alaunos Therapeutics announces board member resignation

April 20, 2025 | investing.com

These 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?

April 7, 2025 | msn.com

Precigen Terminates License Agreement With Alaunos Therapeutics

October 11, 2024 | marketwatch.com

After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen

October 11, 2024 | fiercebiotech.comF

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

October 11, 2024 | finance.yahoo.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest Report

September 26, 2024 | benzinga.com

Alaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News Summary

September 26, 2024 | benzinga.com

Stella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo Finance

September 24, 2024 | finance.yahoo.com

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024

May 15, 2024 | investorplace.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 12, 2024 | seekingalpha.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 8, 2024 | investorplace.com

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

April 1, 2024 | msn.com

Sharp increase in TCRT’s short interest leads to surge in days-to-cover ratio

February 1, 2024 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT, SLGL, LGVN, and CMMB Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$1.14 -0.01 (-0.87%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$1.14 0.00 (0.00%)

As of 07:24 AM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Longeveron NASDAQ:LGVN

$1.46 -0.01 (-0.68%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.34%)

As of 07:31 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Sol-Gel Technologies NASDAQ:SLGL

$8.18 +0.16 (+1.93%)

Closing price 07/16/2025 03:57 PM Eastern

Extended Trading

$8.18 0.00 (0.00%)

As of 07/16/2025 04:04 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Alaunos Therapeutics NASDAQ:TCRT

$3.25 -0.13 (-3.85%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$3.30 +0.06 (+1.69%)

As of 07/16/2025 05:49 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time